A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901.
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Lorvotuzumab mertansine (Primary)
- Indications Carcinoid tumour; Neuroendocrine carcinoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors ImmunoGen
- 31 Aug 2018 Biomarkers information updated
- 09 Mar 2016 Results published in the Investigational New Drugs
- 25 Mar 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov reocrd.